' New Standard of Care ' for HER2-Mutant NSCLC? ' New Standard of Care ' for HER2-Mutant NSCLC?

Patients with non –small cell lung cancer harboring HER2 mutations experienced durable activity and promising survival outcomes with trastuzumab deruxtecan, a new study shows.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news